Aussichtsreiche Werte! - 500 Beiträge pro Seite (Seite 2)

[lofty]

BYD

Bradley Pharmaceuticals Reports Sales Up 102% and Earnings up 152%
Thursday October 30, 7:48 am ET


FAIRFIELD, N.J., Oct. 30 /PRNewswire-FirstCall/ -- BRADLEY PHARMACEUTICALS, INC. (NYSE: BDY - News) today announced that Net Sales for the Third Quarter 2003, ended September 30, totaled $19,983,000, representing an increase of $10,088,000, or 102% over the same period last year. Third Quarter 2003 Net Income reached $5,058,000, an increase of $3,050,000, or 152%, over Third Quarter 2002 Net Income of $2,008,000. Net Income per diluted common share totaled $0.39, compared to $0.18 for the same three-month period in 2002.
Net Sales for the first three quarters of 2003 increased to $51,248,000, a $22,704,000, or 80%, increase over Net Sales for the first three quarters of 2002. Net Income for the first nine months of 2003 reached $11,309,000, representing an increase of $5,785,000, or 105%, over the same period one year ago. Net Income per diluted common share for the first nine months of 2003 totaled $0.94 versus $0.48 for the first nine months of last year.

President and CEO Daniel Glassman, stated, "The Third Quarter 2003 sales and income can largely be attributed to increased prescriptions for therapies from both the Doak Dermatologics and Kenwood Therapeutics operating units. The Doak subsidiary performance was paced by the CARMOL®40 family including a significant increase in prescriptions for CARMOL®40 Gel as well as a strong performance from LIDAMANTLE® and LIDAMANTLE® HC. The continued acceptance of ROSULA® AQUEOUS GEL and the launch of ROSULA® AQUEOUS CLEANSER also helped contribute to Doak`s results. Prescriptions for the Kenwood division have also increased, particularly for ANAMANTLE® HC hemorrhoid therapy. In the Third Quarter 2003, Kenwood Therapeutics launched PAMINE® Forte 5 mg, an effective, well-tolerated GI motility therapy available in a convenient Dose Pack, which is demonstrating considerable physician acceptance."

Management expects to launch new therapies in the Fourth Quarter 2003 and into 2004, and expects that these launches will contribute to sales in upcoming periods. Before the end of 2003, Kenwood expects to launch another new therapy, a moisturizing saline nasal gel. The Doak subsidiary also is preparing to introduce several new therapies during Fourth Quarter 2003 and First Half 2004.

Results of Operations

NET SALES for the three and nine months ended September 30, 2003 were $19,983,000 and $51,248,000, respectively, representing an increase of $10,088,000 from the three months ended September 30, 2002 and an increase of $22,704,000 from the nine months ended September 30, 2002.

For the three months ended September 30, 2003, Doak Dermatologics` net sales increased $8,982,000, led by new product sales from ROSULA(TM) Aqueous Gel, launched in First Quarter 2003, of $850,000 and ROSULA(TM) Aqueous Cleanser, launched in Third Quarter 2003, of $2,798,000 and same product sales volume growth from CARMOL®40 Cream of $1,451,000, CARMOL®40 Lotion of $1,019,000, CARMOL®40 Gel of $1,329,000 and LidaMantle® and LidaMantle® HC of $1,179,000. For the three months ended September 30, 2003, Kenwood Therapeutics` net sales increased $1,106,000, led by new product sales of AnaMantle(TM) HC, launched in First Quarter 2003, of $1,102,000 and Pamine® Forte 5mg, launched in Third Quarter 2003, of $601,000. The total net sales for CARMOL®40 Cream, Lotion and Gel for the three months ended September 30, 2003 were $9,168,000.

For the nine months ended September 30, 2003, net sales for Doak Dermatologics increased $18,586,000, which includes new product sales of ROSULA(TM) Aqueous Gel of $3,096,000 and ROSULA(TM) Aqueous Cleanser of $2,798,000 and same product sales increases of CARMOL®40 Cream of $6,574,000, CARMOL®40 Lotion of $2,734,000, CARMOL®40 Gel of $1,573,000 and LidaMantle® and LidaMantle® HC of $2,036,000. For the nine months ended September 30, 2003, net sales for Kenwood Therapeutics increased $4,118,000, which includes new product sales of AnaMantle(TM) HC of $2,299,000 and Pamine® Forte of $601,000 and same product sales increases in respiratory products of $511,000 and Pamine® 2.5mg of $716,000. The total net sales for CARMOL®40 Cream, Lotion and Gel for the nine months ended September 30, 2003 were $25,164,000.

COST OF SALES for the three and nine months ended September 30, 2003 were $1,608,000 and $4,316,000, respectively, representing an increase of $575,000 from the three months ended September 30, 2002 and an increase of $1,086,000 from the nine months ended September 30, 2002. The gross profit percentage for the three and nine months ended September 30, 2003 was 92% for each period, as compared to 90% and 89% during the three months and nine months ended September 20, 2002, respectively. This increase in gross profit percentage reflects a change in our sales mix, with greater sales of existing prescription products, including CARMOL®40 products, and the new prescription product launches in 2003.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES for the three and nine months ended September 30, 2003 were $9,619,000 and $27,443,000, respectively, representing an increase of $4,243,000, or 79%, compared to the three months ended September 30, 2002 and an increase of $11,801,000, or 75%, compared to the nine months ended September 30, 2002. The increase in selling, general and administrative expenses reflects increased spending on sales and marketing to implement our strategy of niche marketing of our dermatology, podiatry and gastroenterology brands, and increases in legal expenses for the three and nine months ended September 30, 2003 of $107,000 and $1,145,000, respectively, compared to the same periods the prior year. The increase in legal expenses was primarily due to current litigation. Selling, general and administrative expenses as a percent of net sales for the three and nine months ended September 30, 2003 were 48% and 54%, respectively, representing a decrease of 6% compared to the three months ended September 30, 2002 and a decrease of 1% compared to the nine months ended September 30, 2002. The decrease in selling, general, and administrative expenses as a percent of net sales is a result of net sales out pacing selling, general and administrative expenses.

DEPRECIATION AND AMORTIZATION EXPENSES for the three and nine months ended September 30, 2003 were $309,000 and $896,000, respectively, representing an increase of $23,000 from the three months ended September 30, 2002 and an increase of $55,000 from the nine months ended September 30, 2003.

INTEREST INCOME for the three and nine months ended September 30, 2003 was $283,000 and $495,000, respectively, representing an increase of $174,000 from the three months ended September 30, 2002 and an increase of $202,000 from the nine months ended September 30, 2002. This improvement was principally due to an increase in interest income from short-term investments generated by investing excess cash.

INTEREST EXPENSE for the three and nine months ended September 30, 2003 was $440,000 and $549,000, respectively, representing an increase of $421,000 from the three months ended September 30, 2002 and an increase of $480,000 from the nine months ended September 30, 2002. The increase is principally due to accrued interest expense during the period payable to convertible note holders. We issued $25 million and an additional $12 million of 4% senior subordinated convertible notes due 2013 on June 11, 2003 and July 24, 2003, respectively.

INCOME TAX EXPENSE for the three and nine months ended September 30, 2003 was $3,233,000 and $7,230,000, respectively, representing an increase of $1,950,000 from the three months ended September 30, 2002 and an increase of $3,699,000 from the nine months ended September 30, 2002. The effective tax rate used to calculate the income tax expense for the three and nine months ended September 30, 2003 and 2002 was approximately 39%.

NET INCOME for the three and nine months ended September 30, 2003 was $5,058,000 and $11,309,000, respectively, representing an increase of $3,050,000, or 152%, from the three months ended September 30, 2002 and an increase of $5,785,000, or 105%, from the nine months ended September 30, 2002. Net income as a percent of net sales for the three and nine months ended September 30, 2003 were 25% and 22%, respectively, representing an increase of 5% compared to the three months ended September 30, 2002 and an increase of 3% compared to the nine months ended September 30, 2002. This improvement was principally due to an increase in net sales, gross profit margin and interest income, partially offset by an increase in selling, general and administrative expenses and interest expense.

Liquidity and Capital Resources

Our cash and cash equivalents and short-term investments were $75,334,000 at September 30, 2003 and $26,009,000 at December 31, 2002. Cash provided by operating activities for the nine months ended September 30, 2003 was $14,870,000. The sources of cash primarily resulted from net income of $11,309,000 plus non-cash charges for depreciation and amortization of $896,000; non-cash charges for amortization of deferred financing costs of $108,000; non-cash compensation for consulting services of $11,000; tax benefit from exercise of non-qualified stock options and warrants of $1,137,000; an increase in accounts payable of $500,000; an increase in accrued expenses of $2,662,000 resulting primarily from an increase in rebates; and an increase in income taxes payable of $1,027,000. The sources of cash were partially offset by an increase in deferred income taxes of $464,000; an increase in accounts receivable of $1,003,000 primarily due to an increase in sales; an increase in inventories of $777,000 primarily due to initial purchases of finished goods of our newly launched products; and an increase in prepaid expenses and other of $537,000 primarily due to prepayment of annual insurance premiums.

Cash used in investing activities for the nine months ended September 30, 2003 was $20,831,000, which was the result of purchases of short-term investments of $27,029,000 and property and equipment of $379,000, partially offset by proceeds from the sale of short-term investments of $6,577,000.

Cash provided by financing activities for the nine months ended September 30, 2003 was $34,600,000, which was principally the result of proceeds from the sale in June and July 2003 of our 4% convertible senior subordinated notes of $37,000,000, proceeds from exercise of stock options and warrants of $943,000 and distribution of treasury shares of $107,000 to fund our 401(k) plan, partially offset by payments of deferred financing costs associated with the sale of convertible senior subordinated notes of $2,677,000; payments of notes payable of $229,000 and purchases of treasury shares of $545,000.

On June 11, 2003, we issued $25 million in aggregate principal amount of our 4% convertible senior subordinated notes due June 15, 2013 (the "Notes") in a private placement transaction. The Notes bear interest at the rate of 4% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, and are convertible into shares of our common stock at any time prior to maturity at a conversion rate of 50 shares of our common stock per $1,000 in principal amount of Notes, which represents a conversion price of $20.00 per share. On or after June 15, 2008, we may, at our option, redeem the Notes, in whole or in part, for cash at a redemption price equal to 100% of the principal amount of Notes to be redeemed, plus any accrued and unpaid interest to the redemption date. On June 15, 2008, holders of the Notes may require us to purchase all or a portion of their Notes for cash at a purchase price equal to 100% of the principal amount of Notes to be purchased, plus any accrued and unpaid interest to such date. In addition, holders of the Notes may require us to purchase all or a portion of their Notes for cash upon certain repurchase events. The Notes are junior to all of our existing and future senior indebtedness and effectively subordinated to all existing and future liabilities of our subsidiaries, including trade payables.

On July 24, 2003, we issued an additional $12 million in aggregate principal amount of Notes. $8 million of the additional Notes related to the exercise in full of the option to acquire additional Notes granted to the initial purchasers of the Notes, and the remaining additional Notes related to a new agreement entered into by us to issue $4 million of Notes to the initial purchasers. The additional $12 million convertible Notes have the same terms as the initial $25 million of Notes. At September 30, 2003, we had accrued $447,000 of interest relating to the Notes, which is included in accrued expenses.

[lofty]

USNA
splitt 2:1 und ab geht die post.
gruß
lofty

[nörner]

@Lofty
Cave! das ist BDY nicht BYD
gruss nörner

[lofty]

@nörner
ok. tippfehler.
gruß
lofty

[kep]

Ariad (ARIA), ein Biotechwert mit enormem Potential und positivem Newsflow:





http://quotes.barchart.com/texpert.asp?sym=ARIA

[lofty]

@kep
nicht schlecht. werde mal ARIA genau beobachten, danke.
mach weiter so.
gruß
lofty

[maccy1]

was ist hier eigentlich los,haben alle das schreiben verlernt????
AIRN geht heut wieder gut die bringen doch am 5.11. zahlen,das schaut gut aus bis jetzt,müssen ja gut werden bei den kursen heute:-)))
Sind denn hier überhaupt noch welche in AIRN investiert???
Gabs irgendwelche news von den ganzen events bezügl AIRN?
Hab irgendwie nix gefunden....
@adera: was meinst du denn wie die zahlen werden???
Gruss

[lofty]

@kep
ARIA
hast ne gute nase gehabt.
ab heute auch dabei.
danke!
gruß
lofty

[kep]

@lofty

Gerne geschehen!!
IMAX +8.95% s. #363 ins Depot genommen.

"Matrix Revolutions" To Open On 60 Imax Screens

By Andy Georgiades Of DOW JONES

NEWSWIRES TORONTO (Dow Jones)--This week`s release of "The Matrix Revolutions" in 60 of Imax Corp.`s (IMAX) giant-screen cinemas worldwide has moviegoers - and investors - abuzz.

Earlier Monday, Warner Bros. Pictures, the film`s distributor, announced the film would open Nov. 5 in 48 Imax theaters in the U.S. and Canada, as well as 12 theaters overseas.

Imax and Warner Bros., a unit of Time Warner Inc. (TWX), announced the agreement to reformat the two sequels to 1999`s "The Matrix" in April.

For the first time, a live-action Hollywood film will debut in both conventional and Imax screens on the same day. This is a milestone long anticipated by the company and its shareholders, made possible by its Imax DMR technology, which converts standard 35mm film into the Imax format without compromising picture quality and clarity.

"The Matrix Revolutions" represents Imax`s largest DMR-release to date. In June, "The Matrix Reloaded" opened in 39 Imax theaters (three weeks after its premiere in the conventional theater network). Last year, "Star Wars: Episode II - Attack of the Clones," opened in 58 Imax theaters.

The theater count is slightly ahead of the 55 that Eric Wold, analyst at Merriman Curhan Ford & Co., was expecting. Wold told Dow Jones that, because the studio decides which theaters are allowed to play the film, the commitment demonstrated by Warner Bros. is further proof that the Imax network is becoming a more accepted channel for the concurrent release of Hollywood blockbuster movies.

Wold doesn`t own Imax share, nor does his firm have an investment-banking relationship with the company.

In his own informal poll of 17 theaters in the U.S., Wold found a great deal of anticpation for "The Matrix Revolutions" in Imax. As of Sunday night, the Imax version of the film had sold out 12% of its first-day shows compared to only 4% for the 35mm version.

He also found that the Imax ticket price averaged $2.80 more, with a theater in San Francisco charging $5.50 above the regular ticket price of $9.50.

On Nasdaq Monday, Imax is up 70 cents, or 7.7%, to $9.75 on about 1.1 million shares. The stock has traded as high as $9.89 Monday, above the 52-week high of $9.75.

[lofty]

@kep
AKAM nicht zu bremsen.
gruß
lofty

[franke66]

all,
was haltet ihr von TGAL??

gruss
franke

[kep]

Jinpan Intl. (JST) sieht sehr gut aus.



http://www.quicken.com/investments/seceval/?p=JST&tag=1

Jinpan International Limited (Amex Symbol `JST`) 20 Cents Cash Dividend Distribution on January 22, 2004.
Monday, November 3, 2003

ENGLEWOOD CLIFFS, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Jinpan International Limited (Amex: JST, news) According to The Board of Directors resolution on October 14, 2003, Jinpan International Limited declared a cash dividend of 40 cents per share of common stock for the year 2004. The company will make the first distributions of $20 CENTS PER SHARE on January 22, 2004, to shareholders record on January 08, 2004.



As the premier manufacturer of cast coil transformers in China, we plan to become a more global company by gaining market shares in the other regions of the world. In addition, we are looking for areas to provide a more complete package to our customers. We look forward to realizing our goals and to continue delivering the greatest value to our customers.

[kep]

ARIAD Reports Third Quarter 2003 Results (vorbörslich +1.07%)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2003--ARIAD Pharmaceuticals, Inc. (ARIA) today announced results for the third quarter of 2003.
Financial Highlights

For the quarter ended September 30, 2003, the Company reported a net loss of $4.4 million, or $0.11 per share, compared to a net loss of $7.8 million, or $0.24 per share, for the same period in 2002. This decrease in net loss is due primarily to lower R&D expenses resulting from the Company`s focus on cancer and the development of its most-promising small-molecule oncology product candidates. The Company ended the third quarter with $22.0 million in cash, cash equivalents, and marketable securities, compared with cash and cash equivalents of $26.9 million at December 31, 2002.

Subsequently, on October 8, 2003, the Company raised $41 million (gross) through the sale of approximately 6.4 million shares of its common stock in a direct equity placement to unaffiliated institutional investors through Lehman Brothers and Rodman & Renshaw.

"With our successful direct equity placement last month, we have significantly increased our financial resources, which will allow us to accelerate the clinical development of our portfolio of small-molecule oncology product candidates," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "Next year, we expect to initiate phase 2 clinical trials of AP23573 to treat specific solid tumors and blood cancers and phase 1 clinical trials of AP23464 to treat certain forms of leukemia and the spread of cancer. We also plan to move forward with the development of AP23841 to treat cancer in bone."

Other Corporate Highlights

ARIAD`s evolution from scientific discovery to clinical development brings the Company closer to its ultimate goal of becoming a successful pharmaceutical business. Achieving that goal will require further expertise in commercial development, manufacturing, marketing and sales, as well as additional capital. Consequently, the most important milestones during the third quarter were the appointment of Paul J. Sekhri, a former Novartis senior executive, to the newly created position of president and chief business officer and the election of two new directors: Athanase Lavidas, the chairman and chief executive officer of Lavipharm Group, a leading European based pharmaceutical and healthcare products company, and Mary Tanner, senior managing director at Bear Stearns & Co. Inc. Collectively, these appointments underscore our recognition that the challenges, which lie ahead, are not the same as those that we have faced in the past. Continued success will depend greatly on the Company`s ability to attract and retain knowledgeable, imaginative, and resourceful pharmaceutical and biotechnology executives to expand our clinical development capabilities and create our commercial infrastructure.

Upcoming oncology meetings will highlight important progress in the development of ARIAD`s most advanced product candidates:

Eighth Annual Society for Neuro-oncology Meeting (November 13-16, 2003),
International Conference on Molecular Targets and Cancer jointly sponsored by the American Association for Cancer Research, the National Cancer Institute, and the European Organization for Research to Treat Cancer (November 17-21, 2003), and
Forty-fifth annual meeting of the American Society of Hematology (December 6-9, 2003).
ARIAD is engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. The Company is developing a comprehensive approach to the treatment of cancer and is primarily focused on a series of product candidates for targeted oncology indications. ARIAD also has an exclusive license to pioneering technology and patents related to the discovery, development and use of drugs that regulate NF-(kappa)B cell-signaling activity, which has been implicated in many major diseases.

Additional information about ARIAD can be found on the web at http://www.ariad.com.

[kep]

Evolving Systems Reports 2003 Third Quarter Results
Net Income of $2.1 Million in Quarter, $6.4 Million Through Nine Months; Fifth Consecutive Profitable Quarter; Cash Increases to $17.3 Million; CEO Succession Plan Announced (vorbörslich +6.71%)


ENGLEWOOD, Colo., Nov. 4 /PRNewswire-FirstCall/ -- Evolving Systems, Inc. (Nasdaq: EVOL - News), a provider of innovative software solutions for operations and systems integration to many of the largest communications companies in the U.S., today announced increased revenue and profitability for both its third quarter and nine-month period ended September 30, 2003.
Third Quarter Results

The Company reported net income of $2.1 million, or $0.15 per basic share and $0.12 per diluted share, in the third quarter compared with net income of $239,000, or $0.02 per basic and diluted share, in the same quarter a year ago. It was Evolving Systems` fifth consecutive profitable quarter.

Revenue in the third quarter grew to $7.1 million, an 8% increase over revenue of $6.6 million in the third quarter a year ago and an 11% sequential increase over revenue of $6.4 million in the second quarter of this year. Revenue from license fees and services in the third quarter was $3.9 million while customer support revenue was $3.2 million.

Total costs of revenue and operating expenses in the third quarter were reduced by 22% to $5.0 million compared with $6.4 million in the third quarter of 2002, when the Company recorded $310,000 in restructuring and other expenses related to reductions in work force. On a sequential basis, total costs of revenue and operating expenses were further reduced by approximately $250,000 from the second quarter. The continued cost reductions reflect management`s ongoing commitment to lowering its costs of operation.

The Company`s cash balance at September 30, 2003 was $17.3 million. Total backlog, including $2.25 million in new orders booked in the third quarter, was $6.9 million, a figure that includes $3.7 million in license fees and services and $3.2 million in customer support. The new orders were principally for LNP and number inventory enhancements for the Company`s tier one wireline and wireless customers. Since most customer support is contracted on an annual basis, customer support backlog declines each quarter until the contracts are renewed at year end. Customer support backlog in the third quarter declined $3.6 million from the second quarter.

Nine Month Results

For the nine-month period ended September 30, Evolving Systems reported net income of $6.4 million, or $0.46 per basic share and $0.41 per diluted share, versus a net loss of $14.0 million, or $1.06 per basic and diluted share, in the same period a year ago. The strong year-to-date profitability reflects the Company`s successful transition to a solutions business model resulting in increased revenue and reduced cost.

Revenue in the nine-month period increased 42% to $22.2 million from $15.6 million in the same period a year ago. Revenue mix included $12.1 million in license fees and services and $10.0 million in customer support.

Total costs of revenue and operating expenses through nine months were reduced by 47% to $15.8 million compared with $29.8 million in the same period in 2002. This improvement included reductions in all expense categories except product development expense, which increased slightly as the Company prepared to meet potential customer requirements related to wireless and wireline portability and number inventory.

CEO Comments

"We are pleased to have extended our positive momentum into the third quarter," said George Hallenbeck, chairman and CEO. "We have demonstrated an ability to achieve profitable growth in a very difficult telecommunications environment and believe we have laid a solid foundation for continued success as the climate in our industry improves over time.

"We expect that success to be driven by a combination of organic and acquisitive growth," Hallenbeck continued. "This growth strategy is the third phase of our plans laid out in 2002 to restructure, then demonstrate sustained profitability, and then achieve profitable growth.

"We have a blue-chip customer base and a strong, core portfolio of products and services anchored by our number portability, number inventory and, with the addition of CMS, our network operations management solutions. In addition, we have an M&A strategy designed to accelerate revenue and earnings growth through the addition of products and services that leverage our solutions business model. We expect our first acquisition -- CMS Communications, Inc., announced yesterday -- will contribute positively to both our top and bottom lines, add key personnel, technology and customer synergies, and will serve as a model for future M&A activity."

Company Ready for Wireless Number Portability

The Company has completed its preparations for Wireless Number Portability (WNP). Hallenbeck commented, "Since nationwide wireless number portability is scheduled to begin in less than three weeks, we currently believe it is unlikely to be delayed again. When WNP begins, the volume of numbers ported is expected to increase dramatically. We have systematically worked with each of our WNP products to be confident that each of them can handle the volume that we and our customers have forecasted. We have also prepared operational support plans, similar to our Y2K planning in 1999, to be prepared to support our customers with any problems that may occur."

Company Announces Succession Plan for CEO Position

Evolving Systems announced plans to appoint Stephen Gartside, executive vice president of sales and operations, to the position of chief executive officer and member of the Board of Directors effective January 1, 2004. Gartside, 38, succeeds Hallenbeck, 61, who will continue in his role as chairman of the board, assume the additional title of chief technology officer and remain as a fulltime member of the executive team.

Gartside has been with Evolving Systems since 2001. He has 15 years of experience in the telecommunications business with both large and small companies. In his last position as senior vice president, corporate development for Terabeam Corporation, he was deeply involved in developing the business plan which resulted in the creation and growth of the company. He was integral in acquiring significant product assets from Lucent and raising over $575 million in private equity. Hallenbeck, who founded Evolving Systems in 1985, will work with Gartside on the CEO transition process.

Hallenbeck commented, "Stephen has earned the CEO role. He was a major architect of the strategy and planning to change the Company`s business model and restructure and rebuild the Company. During the last year, he has been responsible for the operation of Evolving Systems and implementing the new strategy from sales through delivery. Under his direction, the Company has turned in the best performance in its history.

"As for myself," Hallenbeck continued, "I am greatly looking forward to concentrating on my new CTO role. I intend to focus on how to use technology to generate revenue and profit. Specifically, I intend to focus on methods to further reduce our operational costs and on obtaining technology that fits our solutions business model and meets the needs of our tier one carrier customers. I believe my technical background combined with the business skills I have acquired over the years have prepared me well for this task." Hallenbeck concluded, "As the largest individual shareholder in the Company, I intend to be an active chairman of the board."

The Company will discuss Q3 financial results, preparations for WNP, the CMS Communications acquisition, and the Company`s growth strategy in more detail during the earnings conference call scheduled for 2:15 Mountain Time today.

Outlook

Evolving Systems is raising its full-year revenue guidance to $27.7 million to $28.7 million versus prior guidance of $27.0 to $28.0 million based on year-to-date results and the acquisition of CMS Communications. This guidance includes minor 2003 revenue contributions from the CMS acquisition. The Company believes it will be profitable in the fourth quarter less one-time charges related to the CMS acquisition. The Company`s cash position will likely decline in the fourth quarter as the Company delivers on its prepaid annual customer support obligations, although the year-end cash balance is expected to be at a significantly higher level than at December 31, 2002.

Because of both the unknown impact of WNP volumes, which are anticipated to start November 24, 2003, and the need to audit the CMS financials to conform with GAAP, Evolving Systems will only provide Q1 2004 guidance at this time. The Company expects to be profitable in Q1 2004 on revenue from the combined companies in the range of $6.5 to $8 million. The Company plans to provide expanded 2004 guidance as part of its Q4 2003 earnings call, the time and date of which will be announced at a later date.

[kep]

@lofty

Auch diesem Biotechwert traue ich viel zu: Geron (GERN)

[kep]

IVAN $6.58 (+25%)!!! War sogar kurz über $7.00.
Hat diese Tollheit Methode??

[maccy1]

Thema AIRN is wohl gegessen zahlen waren eher schlecht als recht nachbörslich schön abgeschmiert:-(((Schade!

[lofty]

@maccy1
glaube ich auch



@kep
GERN
finger weg. bios sind nicht die lieblinge der börse.

gruß
lofty

[kep]

@maccy1

AIRN zahlen waren eher schlecht als recht


Dein Satz wird sich leider als der Euphemismus des Tages entpuppen. Weg mit dem Zeugs.

[lofty]

habe keine, muss auch nichts verkaufen

[kep]

@lofty

habe keine [AIRN], muss auch nichts verkaufen

You lucky devil you!

[Mike199]

ich würde mich wegen den nicht so gut ausgefallenen Q3-zahlen nicht entmutigen lassen.

zwar bin auch ich wie die meisten von einer positiven überraschung anstelle einer negativen bezüglich der quartalszahlen ausgegangen doch sprechen überwiegend 2 gründe für mich weiterhin investiert zu bleiben:

1.) die aktie ist in den vergangenen tagen sehr stark gestiegen so dass trotz der enttäuschenden zahlen die aktie auch nicht weniger wert ist als beispielsweise noch vor rund einer woche. auf längere sicht gesehen wird der kurs meiner meinung nach weiter anziehen sobald wieder neue auftragseingänge hereinflattern. die schlechten zahlen sind jetzt im kurs enthalten und wie sagt man so schön: die börse hat kein gedächtnis. also ist doch alles wie vor einer woche, in den nächsten monaten wird es sicherlich bald wieder bergauf gehen mit dem kurs.

2.) beachtlich finde ich auch, dass das gesamtvolumen der an der nasdaq gehandelten airn-aktien gerade einmal 375.000 stück beträgt. betrachtet man die umsätze der vergangenen monate juni, juli, august so ist das nur ein bruchteil des damaligen volumen.
fallende kurse bei relativ gerigen umsätzen meiner meinung nach heute (dafür dass die zahlen veröffentlicht worden).

ich spekuliere auf weiter steigende kurse in den kommenden monaten!!!

gruß,

mike

[ADERA]

@all

AIRN

Airspan Networks Announces Third Quarter Financial Results and Letter of Intent to Acquire Nortel Networks Fixed Wireless Access Business
Related Stocks
• AIRN





BOCA RATON, Fla.--(BUSINESS WIRE)--Nov. 5, 2003--Airspan Networks Inc. (AIRN - news) today announced third quarter financial results for the period ending September 28, 2003. The company reported revenues for the third quarter of $6.3 million. The net loss attributable to common stockholders for the third quarter of 2003 was $0.19 per share, versus a loss of $0.30 per share in the second quarter of 2003 and a loss of $0.14 per share in the third quarter of 2002.

Third quarter revenues were $6.3 million, compared to the $7.5 million recorded in the second quarter of 2003 and $9.0 million recorded in the third quarter of 2002. Gross profit for the third quarter was $0.6 million, or ten percent of revenue, compared to a gross loss of $2.6 million for the preceding quarter. The company recorded a gross profit of $2.5 million, or 28 percent of revenue, for the third quarter of 2002. Operating expenses for the third quarter 2003 totalled $7.8 million, compared to $8.9 million in the second quarter of 2003 and $8.1 million in the third quarter of 2002.

The company`s cash balance at the close of the third quarter 2003 stood at $36.6 million, of which $1.4 million was restricted cash. Total cash usage in the third quarter was approximately $3.2 million.

"The decline we saw in revenue in the third quarter was due to changed timing on several larger pending projects," said Eric Stonestrom, president and chief executive officer of Airspan. "Our third quarter revenues grew over the second quarter 2003 in Europe and the Americas, but fell in Africa. Revenues in Asia were flat compared to the second quarter 2003, with increased China revenues offsetting lower revenues from New Zealand due to project phasing there. The growth in the number of countries where we are selling WipLL, which is now available in a range of frequencies not matched by any competitor, also confirms the potential for this product line worldwide."

For the nine-month period ended September 28, 2003, revenue totalled $21.6 million versus $15.1 million in the corresponding period last year, an increase of 44 percent. Gross profit was 3 percent for the 2003 period and 9 percent for 2002, including provisions for inventory in both periods. Operating expenses totalled $25.5 million for the nine months of 2003 compared to $26.2 million for the corresponding period in 2002. Net loss for the first nine months of 2003 was $22.8 million, or $0.65 per share, compared with a net loss of $23.5 million, or $0.67 per share, for the same period in 2002.

"While the quarter revenues did not meet our expectations, we are pleased with the improvements in the business metrics we control directly," explained Peter Aronstam, chief financial officer. "Our inventory and receivables continue to fall. Our operating costs are also declining, as we continue to find efficiencies by reducing headcount. Operating expenses in the quarter were $1.1 million lower than the second quarter 2003. The improvements in working capital and operating expenses translate into the low cash burn we saw in the quarter. We expect to see further improvements in these metrics for the underlying business in the next quarter."

Eric Stonestrom continued, "The Company today announced plans to acquire Nortel Networks` fixed wireless business. We expect to close the deal in the fourth quarter. Upon closing, this acquisition will give us an additional substantial revenue base going forward as well as a relationship with one of the world`s largest fixed wireless operators. Our strategy to develop a profitable business will be strengthened by this acquisition. The combination of a modestly improving business for our current products together with the new revenue stream will provide a roadmap to profitability. Airspan is expecting revenue growth for 2003 year over year on a full year calendar basis, and the acquisition will have a significant effect on next year`s results. The fourth quarter revenues may or may not be impacted by this acquisition depending on timing of close, and we expect fourth quarter revenues from our existing businesses will be flat with the third quarter. As recently shown in our Intel announcement, we are also investing significant resources in the WiMAX initiative, which is expected to expand the addressable market further in the 2005 timeframe."

The company has scheduled an investor conference call for 5 p.m. EDT today. The dial-in numbers for the live conference call are as follows: US toll-free number is 1-800-565-7630; international access dial-in number is 1-703-464-5615. There will be a live webcast of the conference call available on the investor relations section of the Airspan Web site at http://www.airspan.com.

For those who cannot listen to the live broadcast, an audio replay of the call will be available on the Airspan Web site for 30 days. A telephone replay of the call will also be available. The US toll-free number for the replay is 1-888-211-2648; international access number for the replay is 703-925-2474. Please reference the Airspan Networks third quarter conference call.

About Airspan Networks

Airspan Networks provides wireless DSL systems and solutions to both licensed and unlicensed operators around the world in frequency bands between 700 MHz to 4 GHz, including both PCS and 3.5GHz. Additionally, Airspan has developed enhanced versions of its WipLL product, which in addition to the 2.4GHz and 3.5GHz ranges, serves licensed operators in the USA in the 700MHz range, and unlicensed operators in the 5.7-5.8GHz range. Airspan continues to evolve its products in order to meet new 802.11b and 802.16a IEEE standards. The company has deployments with more than 120 operators in more than 60 countries. Airspan`s systems are based on radio technology that delivers excellent area coverage, high security and resistance to fading. Airspan`s systems can be deployed rapidly and cost effectively, providing an attractive alternative to traditional wired communications networks. Airspan also offers radio planning, network installation, integration, training and support services to facilitate the deployment and operation of its systems. Airspan is headquartered in Boca Raton, Florida with its main operations center in Uxbridge, United Kingdom. More information on Airspan can be found at http://www.airspan.com

Except for historical matters contained herein, this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements made in this press release that are forward-looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. The forward-looking statements also include statements concerning certain anticipated restructuring activities for the fourth quarter of 2003, Airspan`s ability to close the acquisition from Nortel Networks and generate revenues from the Nortel Networks customer base, to improve operating efficiencies and return to profitability and Airspan`s ability to seize growth opportunities, and are subject to risks and uncertainties that could cause actual results to differ materially. Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) a slowdown of expenditures by communication service providers; (ii) increased competition from alternative communication systems; (iii) the failure of our existing or prospective customers to purchase products as projected; (iv) our inability to successfully implement cost reduction or containment programs; and (v) a loss of any of our key customers. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2002.
Airspan Networks Inc

Consolidated Balance Sheets
(in thousands)

December 31, September 28,
2002 2003
------------ -------------
(unaudited)
ASSETS

Current Assets
Cash and cash equivalents $48,167 $35,256
Restricted cash 2,146 1,380
Short term investments 5,074 -
Accounts receivable 14,328 12,030
Unbilled accounts receivable 152 97
Inventory 17,627 11,352
Prepaid expenses and other current assets 3,914 3,325

------------ -------------
Total Current Assets 91,408 63,440

Property, plant and equipment, net 4,137 3,351
Goodwill, net 784 784
Intangible assets, net 626 496
Other non-current assets 906 941

------------ -------------
Total Assets $97,861 $69,012
============ =============

LIABILITIES AND STOCKHOLDERS` EQUITY

Current Liabilities
Accounts payable $7,759 $5,837
Accrued taxes 481 740
Deferred revenue 922 471
Other accrued expenses 8,099 7,083
Current portion of long-term debt 2,500 -

------------ -------------
Total Current Liabilities 19,761 14,131
------------ -------------

Stockholders` Equity
Common stock 10 11
Note receivable - stockholder (130) (130)
Additional paid in capital 214,727 215,141
Treasury stock (405) (797)
Other comprehensive income 1,562 1,101
Accumulated deficit (137,664) (160,445)

------------ -------------
Total Stockholders` Equity 78,100 54,881
------------ -------------

------------ -------------
Total Liabilities and
Stockholders` Equity $97,861 $69,012
============ =============


Zahlen waren nicht so doll.
Wurde bei 2,75$ ausgestoppt! Habe aber trotzdem nen guten Schnitt gemacht. Ich hoffe ihr auch.

Gruß
ADERA

[lofty]

@adera
du klammerst dich zu sehr an airn.
versuche deinem thread neue impulse zu geben.
gruß
lofty

[ADERA]

@all

Solltet ihr im Auge behalten:

ICOS,NITE,LEXR,XING,ELX,NXTL.

Gruß
ADERA

[lofty]

@adera

aussichtreiche sollten hier vorgestellt werden. so lautet dein thread. besserung ist angesagt. bist aber auf dem richtigen weg. etwas mehr gas geben. ok?
gruß
lofty

[ADERA]

@lofty

Ich habe zu wenig Zeit, um mich da rein zu hängen.
Kann das nur sporadisch machen.

Gruß
ADERA

[kep]

Gibt`s keine aussichtsreichen Werte mehr? Wie wär`s mit
OmniVision Technologies (OVTI) (Zack`s Rating: strong buy, heute +6.2%,): Positiver Newsflow, starke fundamentals, zwar kein Schnäppchen mehr allerdings auch nicht exhorbitant.

OmniVision Technologies, Inc. (OVTI) designs, develops and markets high performance, high quality and cost efficient semiconductor imaging devices for computing, communications and consumer electronics applications. OVTI recently announced that it is updating its guidance for revenue and earnings per share for the second quarter of fiscal 2004, ending October 31, 2003. Benefiting from strong demand from the digital-still-camera, video-game, and cell-phone markets, OmniVision projects that revenue will meet or exceed $65 million and that fully diluted earnings per share will meet or exceed 30 cents. The company`s prior target ranges, provided on August 20, 2003, were for revenue of $48 million to $50 million and fully diluted earnings per share of 22 cents to 23 cents. The company plans to report results on November 19th. For the full fiscal year of 2004, analysts have upped their estimates by about 8 cents per share or +8.5% over the past 7 trading days. Earnings growth for next year is projected to be almost +47% over fiscal 2004. It looks like the company is heading in the right direction and it might be some time before it changes.


Siehe auch http://quotes.barchart.com/texpert.asp?sym=OVTI





Wie beurteilt Ihr den Chart? Muss das Gap geschlossen werden?

[kep]

Irgendwas ist da schief gelaufen. Hier der Chart:

[Andue]

@all,

hat jemand Infos zu dem Wert Internap Network (INAP)
US45885A1025.


Grüße
Andue

[MONSIEURCB]

@andue:
http://quotes.barchart.com/texadv.asp?sym=INAP

Sieht ja ganz NETT aus.... :->

[ADERA]

@all

ONNN

Bricht aus!





Gruß
ADERA

[Andue]

@monsieurcb,

Danke für den Link.

Grüße
Andue

[ADERA]

CAAS

Sieht weiter stark aus! Dabei bleiben!

SL nicht vergessen!



Gruß
ADERA

[Techseeker]

Bei 2.00 und 2.40 wollte sie keiner von Euch haben ...



12.12.2003
UMS fast geschenkt
Prior Börse

Die Experten der " Prior Börse" halten die Aktie von UMS (ISIN DE0005493654/ WKN 549365) auf dem aktuellen Kursniveau für fast geschenkt und empfehlen den Investoren auf eine schnelle Kursverdopplung zu setzen.

Dem Vermieter von medizintechnischen Geräten sei nach einem radikalen Schnitt der Turn-Around gelungen. So habe sich im dritten Quartal das Ergebnis von minus 517.000 Euro auf plus 366.000 Euro erhöht. Trotz der US-Dollar-Schwäche sei der Umsatz von Januar bis September um 21 Prozent auf 48 Mio. Euro gestiegen. Inzwischen erwirtschafte der mobile Krankenhaus-Dienstleister fast 70 Prozent seiner Umsätze in den USA.

Die Hanseaten hätten mit dem staatlichen Gesundheitsdienst National Health Services aus England ein Rahmenabkommen geschlossen. So könnten sich demnächst auch bei den Briten die Geschäfte schwungvoll entwickeln. Ferner kooperiere die irische Tochter mit dem führenden privaten Krankenversicherer Voluntary Health Insurance (VHI), was die Auslastung der UMS-Geräte auf der grünen Insel ebenfalls erhöhen dürfte.

Der Börsenwert von UMS in Höhe von 25 Mio. Euro entspreche lediglich dem Wert des Eigenkapitals. In Anbetracht des erwarteten Umsatzes von ca. 63 Mio. Euro sei die Bewertung ein Witz. Und trotzdem müssten sich die Anleger auf ein schwächeres viertes Quartal einstellen. Man gehe davon aus, dass eine Einmalzahlung an die VHI in Irland und zahlreiche Feier- und Urlaubstage in den Krankenhäusern in der sonst so dynamischen Entwicklung ihre Spuren hinterlassen würden. Allerdings dürfte es ab dem ersten Quartal 2004 wieder stramm nach oben gehen.

Es wird von den Experten der " Prior Börse" empfohlen, auf eine schnelle Kursverdopplung der UMS-Aktie zu setzen.


Das wären 8 Euro, oder ?

[Techseeker]

bezgl. 535 ...

das Ding kost jetzt 7.50 Euro ...

[ADERA]

@Techseeker

Ähnlich bei Airspan Networks! Die wollte bei 2$ auch keiner haben



Gruß
ADERA

[ADERA]

MNMM

[ADERA]

MTE

[ADERA]

CHKP

[MONSIEURCB]

@all:
Passt wohl ganz gut in diesen thread - hab mich gerade damit eingedeckt: Consolidated Minerals (WKN 865382)

Consolidated Minerals results surge on demand from China
Source: PERTH, Feb 17 AAP
Published: Tuesday February 17 2004, 4:45 PM

China`s burgeoning steel industry is expected to power a record second half for manganese and chromite producer Consolidated Minerals Ltd.

The company today reported an unaudited after tax profit of $7.25 million for the first half of the current financial year, up 40 per cent on its 2002/03 first half net profit of $5.2 million.

Managing director Michael Kiernan is expecting the next six months to be even better on the back of snowballing demand from China, for manganese and chromite, which reached record levels during the December quarter.

China represents the major market for exports from the company`s flagship Woodie Woodie manganese mine, in Western Australia, and Coobina chromite mine, also in WA.

"We are seeing continued growth in the Chinese steel industry as well as major capacity expansions in its stainless steel sector," Mr Keirnan said.

The Perth company`s foreign exchange hedging program offset the impact of the Australian Dollar during the last six months of 2003/04, he said.

"The combination of commodity price increases coupled with our foreign exchange hedging program will ensure that we realise maximum benefit from current market conditions.

"This should translate into a record financial performance in the second half."

Manganese production for the first half of 2003/04 was 303,500 tonnes and chromite output rose to 121,500 tonnes.

The company`s sales revenue for the first six months of 2003/04 lifted 16 per cent to $53.3 million against $45.9 million in the previous corresponding period.

Consolidated Minerals expects to achieve increases in prices for its manganese equating to the recent 18.62 per cent hike in the benchmark iron ore price for 2004/05.

The company will pay a fully franked three cent interim dividend, up from 2.25 cents previously.

[benefactor [KommA]]

Bist du deinen AIRN treu geblieben ADERA?
Wenn ja, kannst du dich jetzt richtig freuen!

[ADERA]

@benefactor

Zu früh geschmissen. Tja, hätte selber nicht gedacht,dass sie so stark steigen wird. Locker 200%. Naja, nachtrauern bringt nix. Aus Fehlern lernen

Bei Mines Management (MNMM) warte ich bis ich schwarz werde

Warten zahlt sich aus. Gibt es genug Beispiele. AIRN war ein gutes.

Gruß
ADERA

[Dere]

@Adera

Ich denke AIRN kommt nochmal runter. Vielleicht wenn ich
dann noch Cash habe gehe ich nochmal rein.

Bin aber momentan nicht so an "Tech" Aktien interessiert.

Lieber MNMM, CDU, Sally Malay. Kann sich aber wieder ändern.

Gruß Dere

[ADERA]

Exellenter Explorer! Solltet ihr Euch unbedingt mal anschauen.

Novawest Resources WKN 564601 (NVE)




Analysten-Bewertung - 09.06.04

Novawest Resources Outperformer

Die Aktie der Novawest Resources gehöre zu den interessantesten Explorationstitel, die derzeit an der TSX Venture gehandelt würden. Mit Finanzierungsprofi Patrick O`Brien als CEO an der Spitze verfüge das kanadische Juniorunternehmen über ein exzellentes Managementteam und ebenso über ausgezeichnete und angesehene Geologen im Advisory Board. In einem soeben veröffentlichten Exklusivinterview mit " Schmider Investments" weise CEO O`Brien darauf hin, dass man sich momentan in Phase 2 eines im vorigen Jahr begonnenen Dreijahres-Programms zur Exploration bestimmter Projekte befinde. Die Raglan-Besitztümer würden in einem Mineralisierungsgürtel liegen, der " Raglan Belt“ heiße und über 340 km lang sei. In unmittelbarer Nachbarschaft hätten Falconbridge Limited und Anglo American, zwei wichtige Minengesellschaften, ebenfalls großflächige Liegenschaften entdeckt, was für die Attraktivität des Gesteinsgürtels spreche. Novawest gehe nach diversen Proben und Untersuchungen von umfangreichen Nickel, Platin und Palladiumvorkommen in seinen Besitztümern aus. Vier zentrale Gründe würden für einen Einstieg in dieses Papier sprechen: 1.Die Expertise des Managementteams sowie des Advisory Boards sei selbst für den Standard hochspezialisierter Explorationsfirmen beeindruckend. 2. Die Gesellschaft sei ausgezeichnet aufgestellt und diversifiziert. Die von langer Hand vorbereitete Ansammlungsstrategie guter Liegenschaften im Raglan Belt zeichne sich aus. Das Unternehmen konzentriere sich auf erstklassige Projektentwicklungen und verzettele sich nicht in internationalen Ausdehnungen wie viele andere Juniorexplorer. 3. Die oftmals übliche Abhängigkeit von wenigen Rohstoffen werde durch die breite Diversifikation in verschiedene Rohstoffarten ausgeglichen. Platin, Palladium und Nickel würden auch zukünftig an den weltweiten Märkten erhebliche Preissteigerungen sehen. 4. Die Arbeiten im Raglan Projekt stünden im nächsten Jahr vor einem vorläufigen Abschluss und damit werde eine Neubewertung dieses Projektes einhergehen. Nach heutigen Erkenntnissen werde diese Neubewertung extrem positiv ausfallen. Übernahmespekulation und neue Akquisitionsaktivitäten wären die Folge - mit erheblichen Auswirkungen auf den Aktienkurs. Die Experten würden für das nächste Jahr ein Kursziel von 0,50 Euro sehen. Dies dürfte äußerst konservativ sein. Bei weiteren Projekterfolgen könnte die 1 Euro Marke noch 2005 fallen. Die weltweiten Rohstoffmärkte würden in den nächsten Jahren breit aufgestellten Explorern wie Novawest gute Unterstützung bieten. Wegen der Marktenge könne es zu deutlichen Kursverlusten und Volatilitäten kommen. Der Anleger sei verpflichtet, seine Positionen aktiv zu überwachen und im ungünstigsten Falle einen Ausstieg in Erwägung zu ziehen. Stopp-Loss Marken sollten gesetzt werden. Man rate zu 0,17 Euro. Die Anlageexperten von " Schmider Investments" bewerten die Aktie von Novawest Resources mit " Outperformer" .



05.04.04 NovaWest kaufen


Die Experten von " Swiss Financial Report" stufen die Aktie von NovaWest (/ WKN 564601) mit " kaufen" ein. Aufgrund des langfristigen Aufwärtstrends bei Rohstoffen seien Explorationsunternehmen momentan sehr gefragt und könnten mit starken Kurssteigerungen aufwarten. Nicht nur die Kurse von Gold und Silber hätten sich in letzter Zeit prächtig entwickelt. Auch die Preise anderer Rohstoffe seien deutlich gestiegen. Zusätzlich sorge der ständig steigende Bedarf an Rohstoffen in Indien und China für Zündstoff. Auf der Suche nach einem weiteren aussichtsreichen Rohstoff-Player sei man auf die kanadische NovaWest Resources gestoßen. NovaWest habe sich in den letzten Jahren viel versprechende Gebiete in den Provinzen Ontario und Quebec gesichert, auf denen umfangreiche Rohstoffvorkommen vermutet würden. Um den Rahmen dieser Empfehlung nicht zu sprengen, fokussiere man sich auf das Hauptprojekt von NovaWest im Raglan Gebiet. Darüber hinaus schlummere weiteres Potential u.a. beim Nickel Royale Projekt, dem Bucke Pipe Diamantprojekt und dem Solarus Gold Projekt. NovaWests Hauptprojekt liege im Zentrum des " Raglan Belt" im Norden der kanadischen Provinz Quebec, in dem bereits signifikante Nickel- und Kupfervorkommen entdeckt worden seien. Einige Branchenexperten würden hier zudem große Platin- sowie Palladiumvorkommen erwarten. NovaWests Besitz liege idealtypisch im Zentrum des " Raglan Belt" und zähle damit zu den aussichtsreichen Projekten in diesem Gebiet. Bis heute habe NovaWest nur einen sehr kleinen Teil seines Besitzes exploriert. Dies sollte sich in den nächsten beiden Jahren ändern. Es werde nämlich mit Hochdruck am Hauptprojekt, dem " Thunder Project" , gearbeitet. Im Oktober 2003 habe NovaWest als Ergebnis eines umfänglichen Sichtungsprogrammes die erfolgreiche Identifizierung nennenswerter Mineralisierungen gemeldet. Die Proben hätten große Ähnlichkeit zu den Ergebnissen der beiden großen Nachbarn aufgewiesen. Die nächsten Bohrarbeiten würden ab Mitte April 2004 beginnen. Insgesamt seien in den nächsten beiden Jahren Investitionen von rund 9 Mio. CAD eingeplant. Angesichts der hervorragenden Lage sei die Wahrscheinlichkeit, dass eine große Nickelader direkt durch das Gebiet von NovaWest führe, sehr groß. Der Erfolg scheine aufgrund der Oberflächenuntersuchungen vorprogrammiert. Das Unternehmen sei mit seinen Projekten hervorragend aufgestellt. Aufgrund der erheblichen Chancen im " Raglan Belt" und der exzellenten strategischen Lage, sehe man die Wahrscheinlichkeit eines Fundes als sehr hoch an. Im Gegensatz zu den Wettbewerbern sei die Aktie aber noch niedrig bewertet. Und neben dem Raglan Projekt habe NovaWest noch andere Asse im Ärmel. Das Volumen der aktuell laufenden Finanzierungsrunde habe bereits zweimal auf nun 1,2 Mio. CAD erhöht werden müssen. Dies spreche für das gestiegene Anlegerinteresse und sollte zudem den Kurs nach unten absichern. Der aktuelle Aktienkurs liege mit 0,45 CAD nur moderat über dem Kurs der neu auszugebenden Aktien. Bei guten Bohrergebnisse werde die Aktie die Marke von 2 CAD schnell hinter sich lassen. Die Experten von " Swiss Financial Report" empfehlen Anlegern nicht lange zu zögern, sondern sofort einen Anfangsbestand der NovaWest-Aktie zu kaufen, bevor die Kurse davonlaufen! Das erste Kursziel liege bei 0,90 CAD innerhalb der nächsten sechs Monaten. Liquidester Handelsplatz sei die Heimatbörse Vancouver, wobei die Aktie auch spesengünstig in Deutschland erworben werden könne.

Quelle: Swiss Financial Report

[merlone]

Auf dem Weg zum Comeback, siehe Thread: VoIP: Net2Phone auf dem Weg zum Top-Player?:

[ADERA]

@merlone

Die Marke von 5,5$ ist interessant. Sollte sie überwunden werden, wäre der Widerstand weg und gleichzeitig der Abwärtstrend gebrochen.

Gruß
ADERA